Please Note: the content and links within this collection are no longer being maintained.

Living cell technologies : finding a path to market for xenotranspiantation therapy


This case examines the research commercialisation process of the biotech company Living Cell Technologies (LCT). The case outlines the process of pre-clinical and clinical trials undertaken by the company as they moved towards commercialising their pig islet cell treatment for Type 1 diabetes including the research and development and manufacturing capabilities the firm had developed. Also the case describes the challenges in bringing a sometimes controversial biotech product to market, including regulatory hurdles, rapid changes to legislation, the impact of public opinion and the difficulties in raising capital, maintaining cash flow and developing a pipeline of opportunities over a long period of commercialisation.

>> Obtain this item from the Business Case Centre

Case Description
Business Case Study NoUA-2013-003
Number of Pages17
CategoryCase study
CompanyLiving Cell Technologies (LCT)
Setting - CountryInternational
Setting - CityAuckland, NZ

SourceAuckland, NZ. Pages: 1 - 18